Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Gabriel Hortobagyi, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Ohio. He is a Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1974 - 1976
Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1971 - 1974
National University of ColombiaClass of 1970
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1975 - 2026
OH State Medical License 1974 - 2018
PA State Medical License 1973 - 1978
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- 7 citationsRace and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain
Journal of the National Cancer Institute. 2025-05-01 - 7 citationsDevelopment and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer
Journal of Clinical Oncology. 2025-03-10 - 9 citationsHeterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.Paolo Tarantino, Gabriel Hortobagyi, Sara M Tolaney, Elizabeth A Mittendorf
JAMA Oncology. 2024-11-01
Press Mentions
MD Anderson Research Highlights for May 8, 2025May 8th, 2025- RSClin Tool N+ Enhances Breast Cancer Risk EstimatesJanuary 23rd, 2025
- World Cancer Day 2023: All You Need to KnowFebruary 4th, 2023
